ReviewAnnals of gastroenterology2011
An overview of lipid abnormalities in patients with inflammatory bowel disease.
Review in Annals of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.Alimentary pharmacology & therapeutics · 2021Pooled it
- Spp24 is associated with endocytic signalling, lipid metabolism, and discrimination of tissue integrity for 'leaky-gut' in inflammatory bowel disease.Scientific reports · 2020Trial
- Metabolic Profiling of the Gut-Brain Axis in a Murine Model of Ulcerative Colitis with Raman Spectroscopy.ACS applied materials & interfaces · 2026Article
- Advancing IBD Management: A Literature Review on the Role of Non-Invasive Blood-Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment.Clinical and translational science · 2026Review
- Serum phosphatidylinositol depletion associates with fecal calprotectin and disease severity in female and male IBD patients.Lipids in health and disease · 2026Article
- T-cadherin as a potential novel regulator of intestinal inflammation and fibrosis.Frontiers in physiology · 2026Review
- Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes.Medicina (Kaunas, Lithuania) · 2025Article
- Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease.Journal of clinical medicine · 2025Article
- Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives.Advances in therapy · 2025Review
- Unveiling the influence of lipidomes on inflammatory bowel disease: a bidirectional mendelian randomization study.BMC gastroenterology · 2025Article
- Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Low-Density Lipoprotein and High-Density Lipoprotein as Biomarkers for Inflammatory Bowel Disease Activity Assessment.International journal of general medicine · 2025Article
- Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.PloS one · 2025Article
- Unique Metabolomic and Lipidomic Profile in Serum From Patients With Crohn's Disease and Ulcerative Colitis Compared With Healthy Control Individuals.Inflammatory bowel diseases · 2024Article
- The molecular subtypes of autoimmune diseases.Computational and structural biotechnology journal · 2024Review
- Oxidized Low-Density Lipoprotein Induces Reactive Oxygen Species-Dependent Proliferation of Intestinal Epithelial Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Comparative Evaluation of Lipid Profile, C-Reactive Protein and Paraoxonase-1 Activity in Dogs with Inflammatory Protein-Losing Enteropathy and Healthy Dogs.Animals : an open access journal from MDPI · 2024Article
- Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.Inflammatory bowel diseases · 2024Article
- Microbiota in Mild Inflammatory Bowel Disease (IBD) Can Be Modulated by Beta-Glucans and Mannanoligosaccharides: A Randomized, Double-Blinded Study in Dogs.Veterinary sciences · 2024Article
- To explore the causal association between the serum lipid profile and inflammatory bowel disease using bidirectional Mendelian randomisation analysis.eGastroenterology · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INFLAMMATORY BOWEL DISEASE (IBD) IS A CHRONIC INFLAMMATORY DISORDER WHICH ENCOMPASSES TWO FORMS OF INTESTINAL INFLAMMATION: ulcerative colitis and Crohn's disease. It is reported that inflammation, carotid intima media thickness, homocysteine and insulin resistance, parameters that are all associated with atherosclerosis, are increased in IBD. On the contrary, it seems that IBD patients exhibit low levels of low density lipoprotein cholesterol and total cholesterol. This review highlights the lipid profiles that occur in IBD patients and summarizes data of studies using regimens that may affect lipid metabolism in these patients.
Indexed as
Identifiers
24713706PMC3959314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.